PFIZER INC

ISIN: US7170811035 WKN: 717081103 Asset 0

Asset Class: Stock



Company Profile

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets Liabilities and equity		Assets Liabilities and equity		Assets Liabilities and equity	
Current assets	43,333,000,000		51,259,000,000		59,693,000,000	
Common stock capital		478,000,000		476,000,000		473,000,000
Fixed assets	183,168,000,000		145,946,000,000		121,783,000,000	
Equity capital of a company		89,288,000,000		95,917,000,000		77,463,000,000
Cash and cash equivalents	2,853,000,000		416,000,000		1,944,000,000	
Accrued liabilities		11,364,000,000		12,062,000,000		15,055,000,000
Other assets	-		-		-	
Current liabilities		47,794,000,000		42,138,000,000		42,671,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		89,419,000,000		59,150,000,000		61,342,000,000
Different income		-		-		-
Other liabilities		13,251,000,000		10,584,000,000		7,233,000,000
Total assets	226,501,000,000	226,501,000,000	197,205,000,000	197,205,000,000	181,476,000,000	181,476,000,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	88,000	83,000	79,000
Equity ratio	39.54%	48.77%	42.83%
Debt-equity ratio	152.90%	105.05%	133.48%

Others			
	2023	2022	2021
Tax Expense Rate	-105.29%	9.58%	7.62%

PFIZER INC

ISIN:	US7170811035	WKN:	717081103	Asset Class:	Stock

Income statement					
	2023	2022	2021		
Turnover	58,496,000,000	100,330,000,000	81,288,000,000		
Net income	2,133,000,000	31,366,000,000	22,415,000,000		
EBIT	1,661,825,100	33,033,728,000	23,663,725,800		
Operating income before taxes	1,058,000,000	34,729,000,000	24,311,000,000		
Cash Flow	8,700,000,000	33,227,000,000	32,580,000,000		
Net interest income	-745,000,000	-1,111,000,000	-1,363,000,000		
Research and development expenses	10,578,000,000	11,426,000,000	13,828,000,000		
Income taxes	-1,114,000,000	3,328,000,000	1,852,000,000		
Result from investments in subsidaries, associates and other	-	-	-		
Revenues per employee	612,679	1,114,147	948,394		

Board of Directors

Members of Management Board

Dan Littman	Member of Board of Directors
Helen Hobbs	Member of Board of Directors
Scott Gottlieb	Member of Board of Directors
Susan Desmond-Hellmann	Member of Board of Directors
Susan Hockfield	Member of Board of Directors
Cyrus Taraporevala	Member of Board of Directors
James Quincey	Member of Board of Directors
James Smith	Member of Board of Directors
Joseph Echevarria	Member of Board of Directors
Ronald Blaylock	Member of Board of Directors
Shantanu Narayen	Member of Board of Directors
Suzanne Johnson	Member of Board of Directors
Albert Bourla	Chairman of Managing Board
Aamir Malik	Member of Executive Committee
Alexandre de Germay	Member of Executive Committee
Chris Boshoff	Member of Executive Committee
Dave Denton	Member of Executive Committee
Douglas M. Lankler	Member of Executive Committee
Lidia Fonseca	Member of Executive Committee
Mikael Dolsten	Member of Executive Committee
Mike McDermott	Member of Executive Committee
Payal Sahni Becher	Member of Executive Committee
Rady A. Johnson	Member of Executive Committee
Sally Susman	Member of Executive Committee